have been conducted with apparently healthy individuals, high-sensitivity CRP (hs-CRP) methods that can accurately divide results within the reference intervals into quartiles or quintiles have been required. These highsensitivity methods usually have used ELISA methodology, and a single in-house ELISA assay was used for several epidemiologic studies (5, 6 ) . This methodology is primarily for research use and generally is not routinely available in clinical laboratories. Standard CRP methods in the clinical laboratory have limits of detection of 3-5 mg/L and are unsuitable for these applications. Recently, several automated hs-CRP assays have been developed that are suitable for routine use in the clinical laboratory. They possess greater precision at low concentrations of CRP. We evaluated the performance characteristics of four of these, including method comparability, using samples from 322 apparently healthy adult blood donors.
Materials and Methods samples
A total of 322 serum samples were collected from 204 male and 118 female blood donors. The median age of the entire group was 32 years with a range of 17-80 years. The median ages of the male and female donors were 37 and 24 years, respectively. Serum was separated from the red cells and stored at Ϫ70°C until analysis. In addition, a total of 50 samples were collected from patients with CRP concentrations Ͼ8 mg/L. All studies with samples from human subjects were approved by the Institutional Review Board of the University of Utah Health Sciences Center.
apparatus
The BN II nephelometer was from Dade/Behring, the IMx analyzer was from Abbott Diagnostics, the IMMULITE analyzer was from Diagnostics Products Corporation, and the IMMAGE nephelometer was from Beckman/Coulter.
assay procedures
All four methods used the manufacturers' reagents as directed. The BN II N High Sensitivity CRP assay utilizes a monoclonal antibody coated to polystyrene particles and fixed-time kinetic nephelometric measurements (18 ) . The BN II nephelometer makes a 1:400 dilution to measure CRP concentrations between 3.5 and 210 mg/L and a 1:20 dilution below 3.5 mg/L. The IMx assay uses an automated microparticle capture enzyme immunoassay with two mouse anti-CRP monoclonal antibodies (19 ) . A 1:50 manual dilution provides a measurable range of 0.05-30 mg/L. The IMx hs-CRP method is not and has never been commercially available. The IMMULITE assay is a twosite chemiluminescent enzyme immunometric assay with one monoclonal and one polyclonal anti-CRP antibody. A 1:100 manual dilution provides a measurable range of 0.1-500 mg/L. The IMMAGE assay uses a polyclonal anti-CRP antibody coated to latex particles and rate nephelometric measurements. The IMMAGE nephelome- Samples for linearity and precision studies were prepared from two serum pools. The low pool was prepared by combining samples from blood donors with hs-CRP concentrations in the lowest quartile. The high pool was prepared by combining patient samples with hs-CRP concentrations of ϳ10 mg/L. The high pool was diluted with the low pool to the following final percentage of high pool: 100%, 75%, 50%, 30%, 20%, 10%, 5%, and 0%. Samples were assayed in duplicate on 10 different days.
data analysis EP Evaluator release 3 software (David G. Rhoads Associates) was used for Deming regression analysis, calculation of r, and S y͉x . hs-CRP concentrations were skewed rightward in samples from blood donors; therefore, percentile values were estimated and hs-CRP concentrations were log transformed for method comparison plots.
Results
To examine the precision and linearity of the four methods in the CRP concentration range of the reference interval, serum pools were prepared as described in Materials and Methods. The precision of each method was assessed using these pools ( Table 1) . The BN II method demonstrated the best precision across the range of concentrations. The IMx and IMMULITE methods showed comparable precision, and the IMMAGE showed the poorest precision of the methods evaluated, with a CV Ͼ20% at a CRP concentration of 2.26 mg/L. The BN II, IMx, and IMMULITE methods were linear down to the lowest concentration tested, which was a pool of the samples from the lowest quartile of hs-CRP concentrations from blood donors (Fig. 1) . The IMMAGE method was linear down to a concentration corresponding to the median value of the group of blood donors. The BN II, IMMULITE, and IMMAGE methods gave comparable results of 9.79, 9.71, and 10.13 mg/L, respectively, for the high pool, whereas the IMx method gave a value of 13.73 mg/L. The BN II and IMx methods gave comparable results of 0.30 and 0.32 mg/L, respectively, for the low pool, whereas the IMMULITE method gave a value of 0.85 mg/L. Regression analysis of the data yielded intercepts that were comparable to the measured values for the low pool ( Fig. 1, legend) . Reanalysis of the data from the BN II, IMx, and IMMULITE methods by regression of only the four highest concentrations, which account for 70% of the CRP range, yielded intercepts of 1.01, 1.38, and 0.80 mg/L, respectively.
The hs-CRP concentrations of 322 serum samples collected from apparently healthy adult blood donors were measured by the BN II, IMx, IMMULITE, and IMMAGE methods simultaneously. Inspection of the data revealed a highly skewed population. Therefore, values for the 25th, Samples were prepared as described in Materials and Methods and run in duplicate on 10 different days. The mean values for each sample were plotted vs the dilution, and linear regression was performed. Regression analysis for the BN II method (A) gave a slope of 9.87, an intercept of 0.42, and an r of 0.997. For the IMx method (B), the slope was 13.33, the intercept was 0.48, and r was 0.997. For the IMMULITE method (C), the slope was 8.86, the intercept was 0.84, and r was 1.000. For the IMMAGE method (D), the slope was 8.59, the intercept was 1.75, and r was 0.997. 50th, 75th, 90th, 95th, and 97.5th percentiles were determined for each method ( Table 2 ). The BN II and IMx methods yielded comparable results for the 25th through the 95th percentiles. The IMMULITE gave slightly higher values than the BN II method for the 25th and 50th percentiles, and comparable values for the 75th through 95th percentiles. The IMMAGE method gave substantially higher values than the other methods for the 50th and 75th percentiles, whereas the 25th percentile value for this group of samples was below the detection limit of the assay. The BN II, IMMULITE, and IMMAGE methods gave comparable results for the 97.5th percentile, whereas the IMx value was higher. When percentiles were determined by gender, values for the 25th and 50th percentiles were comparable, whereas values for the 75th, 90th, and 95th percentiles were nearly twice as high for women as for men. Because of the limited sample size, the 97.5th percentile was not determined by gender. When the relationship between age and hs-CRP was examined using the BN II method, the Pearson correlation coefficient (r) was 0.238 (P Ͻ0.001).
The agreement of the four methods with samples from blood donors was assessed graphically (Fig. 2) . The BN II method previously had been compared with an in-house ELISA method that was used in several hs-CRP epidemiologic studies and has been validated clinically (18, 20 ) . Furthermore, it is the only method approved by the FDA for cardiovascular and peripheral vascular risk assessment. Therefore, it was chosen as the comparative method when evaluating the other three methods. Deming regression analysis was performed on all data before log trans- (Table 3) indicate that the mean differences and SDs of the differences for the lowest three quartile were lowest between IMx and the comparative method, intermediate between the IMMULITE and the comparative method, and highest for the IMMAGE. For the highest quartile, these values were lowest for the IMMULITE method, followed by the IMx and then the IMMAGE method. All methods showed statistically significant differences from the comparative method (P Ͻ0.05) except for the IMMULITE method with the highest quartile.
The four methods were compared using samples with increased concentrations of CRP (Fig. 3) . All methods showed excellent agreement at CRP concentrations up to 50 mg/L. Above this concentration, there appeared to be considerably more scatter in the data. Both the IMx and IMMULITE methods showed differences with the BN II method Ͼ2 SD at concentrations Ͼ150 mg/L that could not be explained by proportional bias alone.
Discussion
The analytic performance characteristics of CRP assays are changing as new clinical applications are being developed. hs-CRP assays are required for atherosclerotic risk prediction in apparently healthy adults. Both accuracy and precision issues need to be addressed. CRP results will most likely be interpreted in quartiles or quintiles for risk assessment. Therefore, hs-CRP assays will also need to be standardized for CRP concentrations of 0.2-10 mg/L so that results obtained in large population studies can be applied to individual patients. A definition of functional assay sensitivity similar to that used for thyroid-stimulating hormone measurement is required to ensure that assays have the requisite precision at low CRP concentrations. We propose that for risk stratification for cardiovascular, cerebrovascular, and peripheral vascular disease, the hs-CRP assay imprecision should be Ͻ10% at a concentration of 0.2 mg/L.
Several previous studies that examined serum CRP concentrations in apparently healthy populations, using highly sensitive ELISA, nephelometric, and turbidimetric methods, have found median values ranging from 0.58 to 1.13 mg/L (5, 18, 19, (22) (23) (24) (25) (26) . The median values deter- (5, 23, 25, 26 ) . Two previous studies found a 90th percentile hs-CRP concentration of 3 mg/L, whereas we found values of 4.1-5.3 mg/L for the four methods we investigated (19, 23 ) . The basis for this difference in the 90th percentiles observed could be attributable to either differences in the populations studied or the methodologies used. The median age of our population was 32 years, whereas the median ages of the two previous studies reporting values for the 90th percentile were not given. A weak positive correlation between age and hs-CRP concentration has been demonstrated (24 ), and we found a similar correlation. This indicates that younger ages are associated with lower hs-CRP values; however, it is unlikely that the previous studies had a median age substantially younger than 32 years. The good agreement between our data and those generated in previous studies for the median and 75th percentiles indicates similar assay calibration and suggests that population differences may explain the higher values we observed for the 90th percentile. When our results were examined after segregation by gender, differences became noticeable at the 75th, 90th, and 95th percentiles. Previous studies that looked at the effect of gender failed to find a significant difference (23, 24 ) . However, a recent study found that estrogen replacement therapy caused a large sustained increase in the hs-CRP concentrations in postmenopausal women (27, 28 ) . The basis for the gender differences observed, particularly as it affects results primarily in higher hs-CRP percentiles in our population, is uncertain, but it may reflect hormonal differences.
All of the methods we investigated have been standardized against the WHO International Reference Standard for CRP Immunoassay 85/506 (29 ) . Agreement between all methods for concentrations above the upper limit of the reference interval was acceptable. The BN II and IMx methods showed excellent agreement across the whole range of hs-CRP concentrations encountered in adult blood donors. The IMMULITE showed acceptable agreement with the BN II method for hs-CRP concentrations at or above the 75th percentile, whereas the IMMAGE method showed good agreement only with hs-CRP concentrations above the 90th percentile. Harmonization of hs-CRP results at concentrations below these values will require further work. For clinical risk stratification and epidemiologic studies, there needs to be agreement between methods across the reference interval down to hs-CRP concentrations of 0.2 mg/L. The BN II and IMx methods currently meet this goal, whereas the IMMAGE and IMMULITE methods do not.
The recoveries observed for the IMx method for serum pools prepared from healthy donors were ϳ30% higher than the other three methods (Table 1 and Fig. 1 ). However, the percentile values for the donor population determined using the IMx were very similar to the other methods with the exception that the IMx gave the highest values of the methods tested for the 95th and 97.5th percentiles, which were 10 -30% higher than the other methods. The IMx method also showed a slope of 1.10 compared with the BN II method for samples from patients with increased CRP concentrations. The intercept observed for the IMMULITE method when measured recoveries were plotted vs dilution for donor serum pools (Fig. 1 ) was higher (ϳ0.4 mg/L) than those for the BN II and IMx methods. This was also reflected in higher values for the 25th, 50th, and 75th percentiles. The modest proportional and constant biases observed for the IMx and IMMULITE methods, respectively, likely result from differences in calibration. A previous comparison between the BN II and Hemagen ELISA methods showed a slope of 0.75 and an intercept of Ϫ0.25 mg/L (18 ) . Although these two hs-CRP methods have been standardized with the same WHO CRP reference material, they exhibit significant differences in the values obtained (24 ) . These authors concluded that although the exact source of differences was uncertain, it was probably attributable to inadequate standardization. We have confirmed this observation with a different group of hs-CRP assays. Further effort is required for the standardization of hs-CRP assays at concentrations comparable to those seen in healthy subjects.
Another issue that merits discussion is the precision of the methods evaluated. The BN II and IMMAGE methods have automated dilutions, whereas the IMx and IMMU-LITE methods both require a manual dilution prepared off-line. The BN II method was the most precise, whereas the IMx and IMMULITE methods showed comparable precision with values in the reference interval. The IM-MAGE method showed the worst precision at low concentrations of CRP, although acceptable precision with CVs Ͻ10% was observed at a CRP concentrations above the 75th percentile of a healthy population. Given the relatively large within-subject variability (CV I ϭ 42%), analytical CVs of 10% or less should be adequate for both clinical and epidemiologic studies (24 ) .
In conclusion, the four hs-CRP methods we evaluated exhibited some differences in results for a healthy population. Additional standardization efforts are required to ensure that results obtained by automated hs-CRP methods used in the clinical laboratory can be related to large-scale epidemiologic studies. Once standardization has been achieved, hs-CRP assays can provide useful data for atherosclerotic risk stratification in apparently healthy individuals.
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